close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

170.64 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
From Charles River Laboratories International, Inc.
Via Business Wire
Evaluating Charles River: Insights From 7 Financial Analysts
 
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Charles River
 
Via Benzinga
Earnings Scheduled For February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. 
Via Benzinga
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River to Perform Plasmid Production for Ship of Theseus
From Charles River Laboratories International, Inc.
Via Business Wire
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Barclays Global Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
The Top 3 Healthcare Stocks to Buy in March 2024
There are still bargains to be had in the medical space. These are three top healthcare stocks to buy today. 
Via InvestorPlace
Betting on Bitcoin: Does Coinbase Stock’s Surge Signal a Buy?
vBitcoin has exploded higher over the past month setting an all-time record. That’s excellent news for Coinbase Global and COIN stock. 
Via InvestorPlace
Thermo Fisher Stock Lights Up The Board, Soars 40% In 5 Months
Thermo Fisher stock has risen more than 40% since October. Additionally, it's closed higher nine of the past 11 trading sessions. 
Via Investor's Business Daily
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
From Charles River Laboratories International, Inc.
Via Business Wire
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore.
Looking for the next generational winner in healthcare stocks? These are three of the top prospects today. 
Via InvestorPlace
Stocks Rebound As Investor Focus Shifts To Earnings, Bitcoin Tops $1 Trillion Value: What's Driving Markets Wednesday?
The U.S. stock market attempted a rebound following Tuesday’s declines, which were sparked by a higher-than-expected inflation report in January, as investors refocused on corporate earnings. 
Via Benzinga
Topics Economy
Charles River Laboratories Stock Surges On Upbeat Annual Outlook, But This Analyst Is Concerned
Charles River Laboratories Q4 2023 revenue: $1.01 billion, down 7.9% YoY, beating consensus. Analysts note mixed Q4 performance, keeping Outperform rating. 
Via Benzinga
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list... 
Via Benzinga
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today